Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-31T11:09:43.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of insulin-like growth factor-1 (IGF-I) level in patients with rheumatic mitral stenosis

Published online by Cambridge University Press:  14 March 2014

Onur S. Deveci ,
Bunyamin Yavuz ,
Omer Sen ,
Ali Deniz ,
Selcuk Ozkan ,
Kursat Dal ,
Naim Ata ,
Salih Baser ,
Kadir O. Akin  and
Metin Kucukazman
...Show all authors
Onur S. Deveci
Affiliation:
Department of Cardiology, Cukurova University Faculty of Medicine, Adana, Turkey
Bunyamin Yavuz*
Affiliation:
Department of Cardiology, Kecioren Teaching and Research Hospital, Ankara, Turkey
Omer Sen
Affiliation:
Department of Cardiology, Kecioren Teaching and Research Hospital, Ankara, Turkey
Ali Deniz
Affiliation:
Department of Cardiology, Cukurova University Faculty of Medicine, Adana, Turkey
Selcuk Ozkan
Affiliation:
Department of Cardiology, Kecioren Teaching and Research Hospital, Ankara, Turkey
Kursat Dal
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
Naim Ata
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
Salih Baser
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
Kadir O. Akin
Affiliation:
Department of Biochemistry, Kecioren Teaching and Research Hospital, Ankara, Turkey
Metin Kucukazman
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
Esin Beyan
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
Derun T. Ertugrul
Affiliation:
Department of Internal Medicine, Kecioren Teaching and Research Hospital, Ankara, Turkey
*
Correspondence: Dr B. Yavuz, MD, Department of Cardiology, Kecioren Teaching and Research Hospital, Kecioren, Ankara, Turkey. Tel: +90 312-3569000; Fax: +90 312 3569002; E-mail: byavuzmd@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Insulin-like growth factor-1 may serve some regulatory function in the immune system. Rheumatic mitral stenosis is related to autoimmune heart valve damage after streptococcal infection. The aim of this study was to assess the level of insulin-like growth factor-1 and its correlation with the Wilkins score in patients with rheumatic mitral stenosis. Methods: A total of 65 patients with rheumatic mitral stenosis and 62 age- and sex-matched control subjects were enrolled in this study. All subjects underwent transthoracic echocardiography. The mitral valve area and Wilkins score were evaluated for all patients. Biochemical parameters and serum insulin-like growth factor-1 levels were measured. Results: Demographic data were similar in the rheumatic mitral stenosis and control groups. The mean mitral valve area was 1.6±0.4 cm2 in the rheumatic mitral stenosis group. The level of insulin-like growth factor-1 was significantly higher in the rheumatic mitral stenosis group than in the control group (104 (55.6–267) versus 79.1 (23.0–244.0) ng/ml; p=0.039). There was a significant moderate positive correlation between insulin-like growth factor-1 and thickening of leaflets score of Wilkins (r=0.541, p<0.001). Conclusions: The present study demonstrated that serum insulin-like growth factor-1 levels were significantly higher in the rheumatic mitral stenosis group compared with control subjects and that insulin-like growth factor-1 level was also correlated with the Wilkins score. It can be suggested that there may be a link between insulin-like growth factor-1 level and immune pathogenesis of rheumatic mitral stenosis.

Keywords

Rheumatic heart diseasemitral stenosisIGF-1Wilkins score
Type
Original Articles
Information
Cardiology in the Young , Volume 25 , Issue 3 , March 2015 , pp. 496 - 500
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Han, VK, D’Ercole, AJ, Lund, PK. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987; 236: 193–197.CrossRefGoogle ScholarPubMed
2. Wahlander, H, Isgaard, J, Jennische, E, Friberg, P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992; 19: 25–32.CrossRefGoogle ScholarPubMed
3. Guron, G, Friberg, P, Wickman, A, Brantsing, C, Gabrielsson, B, Isgaard, J. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension. Hypertension 1996; 27: 636–642.CrossRefGoogle ScholarPubMed
4. Schillaci, R, Brocardo, MG, Galeano, A, Rolda´n, A. Downregulation of insulin-like growth factor-1 receptor (IGF-1R) expression in human T lymphocyte activation. Cell Immunol 1998; 183: 157–161.CrossRefGoogle ScholarPubMed
5. Wilkins, GT, Weyman, AE, Abascal, VM, Block, PC, Palacios, IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60: 299–308.CrossRefGoogle ScholarPubMed
6. Braunwald, E. Valvular heart disease. Braunwald zipes libby. Heart Disease: A Textbook of Cardiovascular Medicine, 6th edn. W. B. Saunders, Philadelphia, 2001; 1643–1653.Google Scholar
7. Zabriskie, JB. Mimetic relationships between group A streptococci and mammalian tissues. Adv Immunol 1967; 7: 147–188.CrossRefGoogle Scholar
8. Segretin, ME, Galeano, A, Rolda´n, A, Schillaci, R. Insulin-like growth factor-1 receptor regulation in activated human T lymphocytes. Horm Res 2003; 59: 276–280.Google ScholarPubMed
9. Smith, TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62: 199–236.CrossRefGoogle ScholarPubMed
10. Berman, JS, Center, DM. Chemotactic activity of porcine insulin for human T lymphocytes in vitro. J Immunol 1987; 138: 2100–2103.CrossRefGoogle ScholarPubMed
11. Drop, SL, Schuller, AG, Lindenbergh-Kortleve, DJ, Groffen, C, Brinkman, A, Zwarthoff, EC. Structural aspects of the IGFBP family. Growth Regul 1992; 2: 69–79.Google ScholarPubMed
12. Cle´ment, S, Refetoff, S, Robaye, B, Dumont, JE, Schurmans, S, Low, TSH. requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology 2001; 142: 5131–5139.CrossRefGoogle ScholarPubMed
13. Han, X, Sosnowska, D, Bonkowski, EL, Denson, LA. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 2005; 129: 185–203.CrossRefGoogle ScholarPubMed
14. Neidel, J, Blum, WF, Schaeffer, HJ, et al. Elevated levels of insulin-like growth factor (IGF) binding protein-3 in rheumatoid arthritis synovial fluid inhibit stimulation by IGF-I of articular chondrocyte proteoglycan synthesis. Rheumatol Int 1997; 17: 29–37.CrossRefGoogle ScholarPubMed
15. Schalkwijk, J, Joosten, LA, van den Berg, WB, van Wyk, JJ, van de Putte, LB. Insulin-like growth factor stimulation of chondrocyte proteoglycan synthesis by human synovial fluid. Arthritis Rheum 1989; 32: 66–71.CrossRefGoogle ScholarPubMed
16. Hamaguchi, Y, Fujimoto, M, Matsushita, T, Hasegawa, M, Takehara, K, Sato, S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008; 35: 2363–2371.CrossRefGoogle ScholarPubMed